(LXS) LANXESS Aktiengesellschaft - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005470405
Rubber, Plastics, Intermediates, Additives, Chemical
LXS EPS (Earnings per Share)
LXS Revenue
Description: LXS LANXESS Aktiengesellschaft
LANXESS Aktiengesellschaft is a German specialty chemicals company with a market capitalization of approximately €2.03 billion. The companys stock is listed on the XETRA exchange under the ticker symbol LXS.
The specialty chemicals industry is highly competitive, and LANXESSs performance is influenced by factors such as global demand for chemicals, raw material prices, and currency fluctuations. Key economic drivers for the company include the automotive and construction industries, as well as the demand for sustainable and innovative chemical solutions.
From a financial perspective, LANXESSs return on equity (RoE) is currently negative, indicating that the company is not generating profits for its shareholders. However, the forward price-to-earnings (P/E) ratio of 14.58 suggests that investors expect the company to return to profitability in the future.
To improve its financial performance, LANXESS may need to focus on optimizing its production costs, investing in research and development to drive innovation, and expanding its presence in growth markets. Key performance indicators (KPIs) to watch include revenue growth, EBITDA margins, and cash flow generation.
From a valuation perspective, LANXESSs stock price has been volatile, with a beta of 1.561 indicating that it is more sensitive to market fluctuations than the overall market. Investors should monitor the companys progress in executing its strategic plans and delivering on its financial targets.
LXS Stock Overview
| Market Cap in USD | 2,512m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
LXS Stock Ratings
| Growth Rating | -36.0% |
| Fundamental | 41.5% |
| Dividend Rating | 1.09% |
| Return 12m vs S&P 500 | -18.3% |
| Analyst Rating | - |
LXS Dividends
| Dividend Yield 12m | 0.40% |
| Yield on Cost 5y | 0.22% |
| Annual Growth 5y | -36.25% |
| Payout Consistency | 88.9% |
| Payout Ratio | 5.3% |
LXS Growth Ratios
| Growth Correlation 3m | -48.1% |
| Growth Correlation 12m | -8.4% |
| Growth Correlation 5y | -86.7% |
| CAGR 5y | -11.56% |
| CAGR/Max DD 5y | -0.17 |
| Sharpe Ratio 12m | -1.09 |
| Alpha | -18.03 |
| Beta | 0.819 |
| Volatility | 38.37% |
| Current Volume | 242.4k |
| Average Volume 20d | 285.7k |
| Stop Loss | 23.2 (-4.3%) |
| Signal | -0.19 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (-165.0m TTM) > 0 and > 6% of Revenue (6% = 368.9m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -2.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.72% (prev 21.18%; Δ 5.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 441.0m > Net Income -165.0m (YES >=105%, WARN >=100%) |
| Net Debt (-323.0m) to EBITDA (530.0m) ratio: -0.61 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (86.3m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 21.19% (prev 18.43%; Δ 2.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.87% (prev 65.25%; Δ 2.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.35 (EBITDA TTM 530.0m / Interest Expense TTM 20.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.16
| (A) 0.19 = (Total Current Assets 2.81b - Total Current Liabilities 1.17b) / Total Assets 8.43b |
| (B) -0.01 = Retained Earnings (Balance) -102.0m / Total Assets 8.43b |
| (C) -0.01 = EBIT TTM -107.0m / Avg Total Assets 9.06b |
| (D) -0.00 = Book Value of Equity -16.0m / Total Liabilities 4.43b |
| Total Rating: 1.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.52
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.30% = 1.15 |
| 3. FCF Margin 1.82% = 0.46 |
| 4. Debt/Equity 0.84 = 2.16 |
| 5. Debt/Ebitda 6.31 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -3.81% = -0.64 |
| 8. Rev. Trend -81.38% = -4.07 |
| 9. Rev. CAGR -13.51% = -2.25 |
| 10. EPS Trend -31.49% = -0.79 |
| 11. EPS CAGR -40.80% = -2.50 |
What is the price of LXS shares?
As of August 31, 2025, the stock is trading at EUR 24.24 with a total of 242,361 shares traded.
Over the past week, the price has changed by -5.02%, over one month by -3.73%, over three months by -10.95% and over the past year by -4.47%.
Over the past week, the price has changed by -5.02%, over one month by -3.73%, over three months by -10.95% and over the past year by -4.47%.
Is LANXESS Aktiengesellschaft a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, LANXESS Aktiengesellschaft (XETRA:LXS) is currently (August 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 41.52 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LXS is around 19.92 EUR . This means that LXS is currently overvalued and has a potential downside of -17.82%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LXS is around 19.92 EUR . This means that LXS is currently overvalued and has a potential downside of -17.82%.
Is LXS a buy, sell or hold?
LANXESS Aktiengesellschaft has no consensus analysts rating.
What are the forecasts/targets for the LXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.9 | 10.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22.3 | -7.9% |
LXS Fundamental Data Overview
Market Cap USD = 2.51b (2.16b EUR * 1.1648 EUR.USD)
Market Cap EUR = 2.16b (2.16b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 625.0m EUR (Cash And Short Term Investments, last quarter)
P/E Forward = 14.5773
P/S = 0.3508
P/B = 0.5521
P/EG = 1.1165
Beta = 1.571
Revenue TTM = 6.15b EUR
EBIT TTM = -107.0m EUR
EBITDA TTM = 530.0m EUR
Long Term Debt = 3.26b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 80.0m EUR (from shortTermDebt, last quarter)
Debt = 3.34b EUR (Calculated: Short Term 80.0m + Long Term 3.26b)
Net Debt = -323.0m EUR (from netDebt column, last quarter)
Enterprise Value = 4.88b EUR (2.16b + Debt 3.34b - CCE 625.0m)
Interest Coverage Ratio = -5.35 (Ebit TTM -107.0m / Interest Expense TTM 20.0m)
FCF Yield = 2.30% (FCF TTM 112.0m / Enterprise Value 4.88b)
FCF Margin = 1.82% (FCF TTM 112.0m / Revenue TTM 6.15b)
Net Margin = -2.68% (Net Income TTM -165.0m / Revenue TTM 6.15b)
Gross Margin = 21.19% ((Revenue TTM 6.15b - Cost of Revenue TTM 4.84b) / Revenue TTM)
Tobins Q-Ratio = -304.7 (set to none) (Enterprise Value 4.88b / Book Value Of Equity -16.0m)
Interest Expense / Debt = 0.30% (Interest Expense 10.0m / Debt 3.34b)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.41 (Total Current Assets 2.81b / Total Current Liabilities 1.17b)
Debt / Equity = 0.84 (Debt 3.34b / last Quarter total Stockholder Equity 3.99b)
Debt / EBITDA = 6.31 (Net Debt -323.0m / EBITDA 530.0m)
Debt / FCF = 29.86 (Debt 3.34b / FCF TTM 112.0m)
Total Stockholder Equity = 4.33b (last 4 quarters mean)
RoA = -1.96% (Net Income -165.0m, Total Assets 8.43b )
RoE = -3.81% (Net Income TTM -165.0m / Total Stockholder Equity 4.33b)
RoCE = -1.41% (Ebit -107.0m / (Equity 4.33b + L.T.Debt 3.26b))
RoIC = unknown (NOPAT none, Invested Capital 5.03b, Ebit -107.0m)
WACC = unknown (E(2.16b)/V(5.50b) * Re(9.03%)) + (D(3.34b)/V(5.50b) * Rd(0.30%) * (1-Tc(none)))
Shares Correlation 5-Years: 0.0 | Cagr: 0.0%
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 66.12% ; FCFE base≈220.8m ; Y1≈145.0m ; Y5≈66.3m
Fair Price DCF = 12.87 (DCF Value 1.11b / Shares Outstanding 86.3m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -81.38 | Revenue CAGR: -13.51%
Rev Growth-of-Growth: 16.31
EPS Correlation: -31.49 | EPS CAGR: -40.80%
EPS Growth-of-Growth: 165.2
Market Cap EUR = 2.16b (2.16b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 625.0m EUR (Cash And Short Term Investments, last quarter)
P/E Forward = 14.5773
P/S = 0.3508
P/B = 0.5521
P/EG = 1.1165
Beta = 1.571
Revenue TTM = 6.15b EUR
EBIT TTM = -107.0m EUR
EBITDA TTM = 530.0m EUR
Long Term Debt = 3.26b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 80.0m EUR (from shortTermDebt, last quarter)
Debt = 3.34b EUR (Calculated: Short Term 80.0m + Long Term 3.26b)
Net Debt = -323.0m EUR (from netDebt column, last quarter)
Enterprise Value = 4.88b EUR (2.16b + Debt 3.34b - CCE 625.0m)
Interest Coverage Ratio = -5.35 (Ebit TTM -107.0m / Interest Expense TTM 20.0m)
FCF Yield = 2.30% (FCF TTM 112.0m / Enterprise Value 4.88b)
FCF Margin = 1.82% (FCF TTM 112.0m / Revenue TTM 6.15b)
Net Margin = -2.68% (Net Income TTM -165.0m / Revenue TTM 6.15b)
Gross Margin = 21.19% ((Revenue TTM 6.15b - Cost of Revenue TTM 4.84b) / Revenue TTM)
Tobins Q-Ratio = -304.7 (set to none) (Enterprise Value 4.88b / Book Value Of Equity -16.0m)
Interest Expense / Debt = 0.30% (Interest Expense 10.0m / Debt 3.34b)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.41 (Total Current Assets 2.81b / Total Current Liabilities 1.17b)
Debt / Equity = 0.84 (Debt 3.34b / last Quarter total Stockholder Equity 3.99b)
Debt / EBITDA = 6.31 (Net Debt -323.0m / EBITDA 530.0m)
Debt / FCF = 29.86 (Debt 3.34b / FCF TTM 112.0m)
Total Stockholder Equity = 4.33b (last 4 quarters mean)
RoA = -1.96% (Net Income -165.0m, Total Assets 8.43b )
RoE = -3.81% (Net Income TTM -165.0m / Total Stockholder Equity 4.33b)
RoCE = -1.41% (Ebit -107.0m / (Equity 4.33b + L.T.Debt 3.26b))
RoIC = unknown (NOPAT none, Invested Capital 5.03b, Ebit -107.0m)
WACC = unknown (E(2.16b)/V(5.50b) * Re(9.03%)) + (D(3.34b)/V(5.50b) * Rd(0.30%) * (1-Tc(none)))
Shares Correlation 5-Years: 0.0 | Cagr: 0.0%
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 66.12% ; FCFE base≈220.8m ; Y1≈145.0m ; Y5≈66.3m
Fair Price DCF = 12.87 (DCF Value 1.11b / Shares Outstanding 86.3m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -81.38 | Revenue CAGR: -13.51%
Rev Growth-of-Growth: 16.31
EPS Correlation: -31.49 | EPS CAGR: -40.80%
EPS Growth-of-Growth: 165.2